Search results for: 'diseas'

Management of infectious diseases remains a critical challenge for public health professionals who face increasing demand to control the spread of existing and novel diseases. To provide appropriate healthcare assistance, it is imperative to diagnose the exact form of infection from an array of complicated symptoms expressed by the host. As the out...

The U.S. Alzheimer's disease medication markets research service provides revenue and patient forecasts, competitive analysis, market trends, product analysis and strategies for growth. The market is segmented by product type into cholinesterase inhibitors, NMDA receptor antagonists and new mechanism drugs. Each of the segments discusses in detail ...

At present, only a few therapies are available with relatively low success. Both, the clinical and the scientific communities are critically devoted to develop new therapeutic approaches to treat and diagnose neurodegenerative diseases. At present days, neurodegenerative diseases represent one of the main causes of death in the industrialized econ...

Respiratory diseases are on the rise globally due to various factors, including environmental ones. Obstructive lung diseases such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis are a huge burden on the global healthcare system. Existing therapies can only reduce the impact and provide short-term relief, but are not ca...

This research service presents an analysis of selected infectious disease IVD in the APAC market. The study is segmented based on the following three main methods of diagnostic technologies used: microbiology testing, immunochemistry, and molecular diagnostics. It provides in-depth analysis of infectious diseases with higher occurrence in the Asia-...

Recent advancement in the development of novel platforms of smart targeting small molecules, gene therapy, stem cell therapy, gene modification, and gene rectification technologies pose new prospects for therapies and cures for rare and genetic diseases. More than 80% of rare diseases are genetic in origin, so that gene and cell therapies are being...

Programmable epigenome editing is developing as a distinct approach to controlling gene activity without changing the underlying DNA sequence. This report examines the landscape from the core editing technologies and delivery systems through the companies, academic programs and therapeutic applications shaping the field. It assesses the competitive...

09 Nov 2022  |  Global  |  Technology Research

Emerging Therapeutics for Rare Neuromuscular Diseases: Pipeline Analysis

Strategic partnering and new product development will enable better biologics for personalized and targeted treatment

Infographics

×

Muscle weakness, cramps, and impaired musculoskeletal functions that occur due to rare defects in nerve and muscle cells characterize neuromuscular disorders (NMDs). The disorders are largely classified as motor neuron diseases, hereditary ataxias, peripheral nerve disorders, neuromuscular junction transmission disorders, and myopathies. NMDs prese...

The drug approvals of Yescarta (axicabtagene ciloleucel), Luxturna (Voretigene neparvovec) and Kymriah (Tisagenlecleucel) have turned a leaf in the pharmaceutical chapter of gene therapy development. Currently, genetic disorders do not have satisfactory treatment outcomes. This is in part due to the inability of small molecule drugs and enzyme repl...